PT  - JOURNAL ARTICLE
AU  - Stephanie Perniciaro
AU  - Mark van der Linden
TI  - Pneumococcal vaccine uptake and vaccine effectiveness in older adults with invasive pneumococcal disease in Germany
AID  - 10.1101/2020.09.25.20201707
DP  - 2020 Jan 01
TA  - medRxiv
PG  - 2020.09.25.20201707
4099  - http://medrxiv.org/content/early/2020/09/27/2020.09.25.20201707.short
4100  - http://medrxiv.org/content/early/2020/09/27/2020.09.25.20201707.full
AB  - Background Invasive pneumococcal disease (IPD) in people ≥60 years old is on the rise in Germany. There has been a recommendation for pneumococcal vaccination in this age group since 1998.Methods We determined the vaccination status of people ≥60 years old with IPD in Germany. We assessed vaccine effectiveness (VE) of the recommended 23-valent polysaccharide vaccine (PPV23).Results The rate of pneumococcal vaccination in older adults with IPD is low, 26%, with only 16% of people receiving a pneumococcal vaccine within the past 5 years. Age- and sex-adjusted vaccine effectiveness (VE) for PPV23 was 37% (95% confidence interval 12% - 55%). For people vaccinated with PPV23 less than 2 years prior to IPD, VE was - 20% (−131% - 34%), between 2-4 years prior to IPD, VE was 56% (20% - 76%), and 47% (17% - 63%) for those vaccinated ≥5 years ago. Excluding serotype 3, overall VE for the remaining serotypes in PPV23 was 63% (49% - 74%). For people receiving PPV23 within the past 2 years, VE against all serotypes except 3 was 49% (12% - 71%); for people vaccinated between 2-4 years prior to IPD 66% (37% - 82%); for those vaccinated ≥5 years ago, 69% (50% - 81%). VE of PPV23 against serotype 3 IPD only was -110% (- 198% - -47%).Conclusions To reduce IPD in older adults in Germany, we must increase the rate of pneumococcal vaccine uptake. For 22/23 serotypes, PPV23 was effective. Serotype 3 remains a major problem.Competing Interest StatementThis study was funded by Pfizer. SP has received travel fees from Pfizer. MvdL has received honoraria, grants, and served on advisory boards for Pfizer and Merck.Funding StatementThis study was funded by an investigator-initiated grant from Pfizer.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The IRB of the University Hospital RWTH Aachen approved this study.All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesFull data for this study will be made available on request.